These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763 [TBL] [Abstract][Full Text] [Related]
8. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering. Jones PH Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial. Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317 [TBL] [Abstract][Full Text] [Related]
10. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Fazio S Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268 [TBL] [Abstract][Full Text] [Related]
11. Clinical trials and lipid guidelines for type II diabetes. Prisant LM J Clin Pharmacol; 2004 Apr; 44(4):423-30. PubMed ID: 15051751 [TBL] [Abstract][Full Text] [Related]
13. Hyperlipidemia in children with type 2 diabetes mellitus. Taha D J Pediatr Endocrinol Metab; 2002 Apr; 15 Suppl 1():505-7. PubMed ID: 12017224 [TBL] [Abstract][Full Text] [Related]
14. Dyslipidemia in type 2 diabetes. Krauss RM; Siri PW Med Clin North Am; 2004 Jul; 88(4):897-909, x. PubMed ID: 15308384 [TBL] [Abstract][Full Text] [Related]
15. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia. Sorensen SV; Frick KD; Wade A; Simko R; Burge R Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159 [TBL] [Abstract][Full Text] [Related]
16. Hyperlipidemia and cardiovascular risk factors in patients with type 2 diabetes. Goldberg RB Am J Manag Care; 2000 Aug; 6(13 Suppl):S682-91; discussion S692-6. PubMed ID: 11183421 [TBL] [Abstract][Full Text] [Related]
17. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus. Betteridge J Am J Med; 2005 Dec; 118 Suppl 12A():10-5. PubMed ID: 16356802 [TBL] [Abstract][Full Text] [Related]
18. Achieving vascular risk factor targets: a survey of a London general practice. Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M Angiology; 2008; 59(1):36-46. PubMed ID: 18319220 [TBL] [Abstract][Full Text] [Related]
19. Lipids in type 2 diabetes. Laakso M Semin Vasc Med; 2002 Feb; 2(1):59-66. PubMed ID: 16222596 [TBL] [Abstract][Full Text] [Related]
20. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]